1. A method of determining the power parts of the codes in different time slots (slot 0, slot 1, . . . ) of CDMA signals transmitted, which includes a pilot channel (CPICH) and at least one dedicated physical channel (DPCH), whereby different orthogonal codes are assigned to the pilot channel (CPICH and the dedicated physical channels (DPCH), and the time slots (slot 14, slot 0, . . . ) of the dedicated physical channels (DPCH) can be shifted in time in relation to the time slots (slot 0, slot 1, . . . ) of the pilot channel (CPICH) with the following steps:
Select an orthogonal code whose power part is to be determined,
Determine whether the orthogonal code selected is active, i.e., whether the code is assigned to a dedicated physical channel,
If the orthogonal code selected is active: determine the power part at the moment and display the momentary power part as a function of the time in the raster of time slots (slot 0, slot 1, . . . ) of the pilot channel (CPICH), and
If the orthogonal code selected is not active: determine the mean power part using the length of the time slot (slot 0, slot 1, . . . ) of the pilot channel (CPICH) and display the mean power part as a function of the time in the raster of time slots (slot 0, slot 1, . . . ) of the pilot channel (CPICH).
2. The method in claim 1, characterized by the fact that the power parts for the orthogonal code in a certain code class (CC), i.e., for all codes with a certain spreading factor (SF), are determined.
3. The method in claim 2, characterized by the fact that the inactive orthogonal codes contain alias power parts of used orthogonal codes in a higher or lower code class (CC), and the mean power part represents the sum of the mean power parts of the used orthogonal codes in a higher code class (CC).
4. The method in one of claims 1 to 3, characterized by the fact that the power of each active dedicated physical channel (DPCH) is changed at the beginning of a pilot sequence (pilot) and the length of the pilot sequence (pilot) depends on the spreading factor (SF).
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition comprising iodide (I\u2212) and a source of hydrogen peroxide, together with a pharmaceutically effective carrier or diluent.
2. The pharmaceutical composition according to claim 1, where the concentration of hydrogen peroxide is less than 1% based on weightvolume or weightweight.
3. The pharmaceutical composition according to claim 1, which does not include a peroxidase enzyme.
4. The pharmaceutical composition according to claim 1 comprising a 0.2:1 to 3:1 ratio by weight of iodide to hydrogen peroxide.
5. The pharmaceutical composition according to claim 1 comprising a 0.38:1 to 1.52:1 ratio by weight of iodide to hydrogen peroxide.
6. The pharmaceutical composition according to claim 1, containing 5-5,000 mg iodide, prepared at a ratio of between 0.2:1 and 3:1 by weight of iodide to hydrogen peroxide.
7. The pharmaceutical composition according to claim 1, containing 5-5,000 mg iodide, prepared at a preferable ratio of between 0.38:1 and 1.52:1 by weight of iodide to hydrogen peroxide.
8. The pharmaceutical composition according to claim 1, containing 5-5,000 mg iodide, prepared at a more preferable ratio of 0.76:1 by weight of iodide to hydrogen peroxide.
9. The pharmaceutical composition according to claim 1, adapted to reach a minimum concentration of 50 mg peroxide and 38 mg iodide per litre of milk, during a milking cycle.
10. The pharmaceutical composition according to claim 1, wherein the source of iodide is sodium iodide or potassium iodide lithium iodide, caesium iodide, hydrogen iodide, rhodium iodide, or a slow-releasing form thereof.
11. The pharmaceutical composition according to claim 1, wherein the source of hydrogen peroxide is hydrogen peroxide, sodium peroxide, lithium peroxide or peroxide releasing citric acid or Vitamin C, peroxide salts including barium oxide, sodium perborate, an hydrogen peroxide-urea adduct, oxygen releasing pseudo peroxides including superoxides, dioygenals, ozones, and ozonides, organic peroxides including peroxy acids, acyl halides, aliphatic peroxides.
12. The pharmaceutical composition according to claim 1, wherein the source of hydrogen peroxide is a peroxide-releasing percarbonate or a slow-releasing form.
13. The pharmaceutical composition according to claim 1, containing 5-5,000 mg iodide, prepared at a ratio of between 0.2:1 and 1:1 by weight of iodide to sodium percarbonate.
14. The pharmaceutical composition as claimed in claim 1, further comprising lactoferrin or a glucocorticoid.
15. The pharmaceutical composition as claimed in claim 12 wherein the glucocorticoid is predinisolone prednisone, or hydrocortisone.
16. The pharmaceutical composition of claim 1, wherein the composition is adapted for the treatment of mastitic lactating ruminant animals.
17. The pharmaceutical composition of claim 1, adapted for concurrent, or sequential, delivery of the peroxide and iodide components.
18. The pharmaceutical composition of claim 1, wherein the pharmaceutically effective carrier is water, saline, an emulsion, a gel or a hydrogel.
19. The pharmaceutical composition of claim 1, adapted for delivery by means of an intra-mammary device.
20. The pharmaceutical composition of claim 1, adapted for delivery by means of a dampened bandage.
21. The pharmaceutical composition of claim 1, wherein the composition is adapted for use as an antimicrobial nasal rinse.
22. The pharmaceutical composition of claim 1, wherein the composition is adapted for use as an antimicrobial mouth-wash.
23. The pharmaceutical composition of claim 1, wherein the composition is added to a bandage or poultice for the treatment of wound or burn infections.
24. The pharmaceutical composition of claim 1, wherein the composition is nebulised in the form of a spray for the treatment of bacterial or fungal infection of the human or animal lung.
25. The pharmaceutical composition of claim 1, wherein the composition is adapted for use as an antifungal wash.
26. The pharmaceutical composition according to claim 1, where hydrogen peroxide and iodide are provided in a concentrated form in a medical device, suitable for production of a working solution containing between 10-5,000 mgL hydrogen peroxide and 7-3,800 mgL iodide.
27. A composition comprising 7-3,800 mgL iodide and 10-5,000 mgL hydrogen peroxide for use as a disinfectant.
28. A medical device coated with the pharmaceutical composition of claim 1.
29. A bandage or poultice impregnated with the pharmaceutical composition of claim 1.
30. A disinfectant or antiseptic composition comprising iodide and a source of hydrogen peroxide.
31. A method of preventing or treating an infection comprising administering to a subject in need of such treatment iodide and a source of hydrogen peroxide, either concurrently or sequentially.